Weill Cornell Medicine Oct 17 2024 It may soon be possible to determine which patients with a type of liver cancer called hepatocellular carcinoma would benefit from immunotherapy , according to a preclinical study by Weill Cornell Medicine investigators. The study, published Oct. 17 in Molecular Cell, provides new insights into a pair of proteins, called p62 and NBR1, and their opposing functions in regulating the interferon response in hepatic stellate cells, a critical immune component in